Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 26 Week Randomised, Parallel Three-arm, Open-label, Multi-centre, Multinational Treat-to-target Trial Comparing Fixed Ratio Combination of Insulin Degludec and Liraglutide Versus Insulin Degludec or Liraglutide Alone, in Subjects With Type 2 Diabetes Treated With 1-2 Oral Anti-diabetic Drugs (OADs)With a 26 Week Extension

NCT01336023 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT01336023
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01336023 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 26 Week Randomised, Parallel Three-arm, Open-label, Multi-centre, Multinational Treat-to-target Trial Comparing Fixed Ratio Combination of Insulin Degludec and Liraglutide Versus Insulin Degludec or Liraglutide Alone, in Subjects With Type 2 Diabetes Treated With 1-2 Oral Anti-diabetic Drugs (OADs)With a 26 Week Extension
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Completed
Start date
May 23, 2011
Completion date
November 22, 2012
Enrollment
1,663 (actual)
Sites
302

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, diabetes mellitus, type 2